Mitochondrial Uncoupling and the Reprograming of Intermediary Metabolism in Leukemia Cells by Juliana Vélez et al.
REVIEW ARTICLE
published: 02 April 2013
doi: 10.3389/fonc.2013.00067
Mitochondrial uncoupling and the reprograming of
intermediary metabolism in leukemia cells
JulianaVélez 1, Numsen Hail Jr.2,3, Marina Konopleva2,3, Zhihong Zeng2,3, Kensuke Kojima2,3,
Ismael Samudio1* and Michael Andreeff 2,3*
1 Grupo de Terapia Celular y Molecular Laboratorio de Bioquimica, Pontificia Universidad Javeriana, Bogotá, Colombia
2 Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Edited by:
Jozsef Dudas, Medical University
Innsbru, Austria
Reviewed by:
Daniel Christian Hoessli, International
Center for Chemical and Biological
Sciences, Switzerland
Jozsef Dudas, Medical University
Innsbruck, Austria
*Correspondence:
Ismael Samudio, Laboratorio de
Bioquimica #301, Edificio Jesús
Emilio Ramírez, Pontificia Universidad
Javeriana, Cra 7 No. 43–82, Bogotá,
Colombia.
e-mail: samudioi@javeriana.edu.co;
Michael Andreeff , Departments of
Leukemia and Stem Cell
Transplantation and Cellular Therapy,
The University of Texas MD Anderson
Cancer Center, 1515 Holcombe Blvd.,
Unit 448, Houston, TX 77030, USA.
e-mail: mandreef@mdanderson.org
Nearly 60 years ago Otto Warburg proposed, in a seminal publication, that an irreparable
defect in the oxidative capacity of normal cells supported the switch to glycolysis for energy
generation and the appearance of the malignant phenotype (Warburg, 1956). Curiously,
this phenotype was also observed by Warburg in embryonic tissues, and recent research
demonstrated that normal stem cells may indeed rely on aerobic glycolysis – fermenting
pyruvate to lactate in the presence of ample oxygen – rather than on the complete oxidation
of pyruvate in the Krebs cycle – to generate cellular energy (Folmes et al., 2012). However,
it remains to be determined whether this phenotype is causative for neoplastic develop-
ment, or rather the result of malignant transformation. In addition, in light of mounting
evidence demonstrating that cancer cells can carry out electron transport and oxidative
phosphorylation, although in some cases predominantly using electrons from non-glucose
carbon sources (Bloch-Frankenthal et al., 1965), Warburg’s hypothesis needs to be revis-
ited. Lastly, recent evidence suggests that the leukemia bone marrow microenvironment
promotes theWarburg phenotype adding another layer of complexity to the study of metab-
olism in hematological malignancies. In this review we will discuss some of the evidence
for alterations in the intermediary metabolism of leukemia cells and present evidence for
a concept put forth decades ago by lipid biochemist Feodor Lynen, and acknowledged
by Warburg himself, that cancer cell mitochondria uncouple ATP synthesis from electron
transport and therefore depend on glycolysis to meet their energy demands (Lynen, 1951;
Warburg, 1956).
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OXIDIZING CARBON SOURCES OTHER THAN GLUCOSE
It has been shown that leukemia cells generate significant amounts
of lactate even in the presence of adequate amounts of oxygen
(Samudio et al., 2008, 2010) recapitulating Warburg’s observations
in Ehrlich’s ascites tumor cells (Warburg et al., 1924). However, in
contrast to what Warburg hypothesized, it is evident that leukemia
cells have the ability to reduce molecular oxygen utilizing electrons
from carbon sources other than pyruvate (Samudio et al., 2008,
2010). This finding is intriguing in light of the finding that in
other tumor types, like glioblastoma, the anaplerotic (see Table 1)
entry of glutamine-derived glutamate fuels the Krebs cycle and
oxidative phosphorylation (OXPHOS) (DeBerardinis et al., 2007),
suggesting that shunting pyruvate away from mitochondrial oxi-
dation may be an acquired trait of different types of cancer. In
the case of leukemia cells, recent evidence suggests that fatty acid-
derived acetyl-CoA fuels Krebs cycle activity and the molecular
reduction of oxygen (Samudio et al., 2010). Unpublished obser-
vations from our group suggest that glutaminolysis is essential
to maintain oxygen consumption in these cells, supporting the
notion that leukemia cell mitochondria are less prone to oxidize
pyruvate (Figure 1). The question arises therefore, what could be
the selective advantage of this metabolic shift?
First, while complete oxidation of glucose in the Krebs cycle
yields more ATP per mole of glucose than does glycolysis, it
fails to safeguard carbon skeletons for anabolic reactions. For
instance, pyruvate transamination produces alanine; alanine accu-
mulation in turn allosterically inhibits pyruvate kinase, and results
in accumulation of phosphoenolpyruvate which via equilibrium
reactions is converted to 3-phosphoglycerate which serves as a
precursor to serine and glycine (reviewed in DeBerardinis, 2011).
Phosphoenolpyruvate is also an inhibitor of phosphofructokinase,
which would shunt fructose-6-phosphate to glucose-6-phosphate
that can now enter the pentose phosphate shunt to produce
NADPH for biosynthesis and ribose-5-phosphate for nucleotide
biosynthesis (Berg et al., 2002). Thus, non-oxidative metabolism of
glucose carbon skeletons is essential for safeguarding biosynthetic
capacity in rapidly proliferating cells.
Second, while the activity of the Krebs cycle has indeed a major
influence in the regulation of OXPHOS-mediated ATP generation
in transformed leukocytes, as these cells proliferate uncontrollably,
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Table 1 | Glossary of terms.
Anaplerosis Replenishing of Krebs cycle intermediates that have been used for anabolic purposes
Cataplerosis Utilization of Krebs cycle intermediates for anabolic purposes
Amphibolic A characteristic of the Krebs cycle that allows it to participate in catabolism of carbon skeletons, while at the same time,
or at distinct moments, providing anabolic intermediates
Allosterism Enzyme regulation (positive or negative) in a site distinct from the catalytic site
OXPHOS Oxidative phosphorylation. The production of ATP in response to an electrochemical proton gradient generated during
electron transport in the mitochondria
Mitochondrial uncoupling The uncoupling of electron transport from ATP synthesis
FAO Fatty acid oxidation; produces large amounts of reducing intermediates FADH2 and NADH, and promotes mitochondrial
uncoupling; odd-numbered fatty acids can provide anaplerotic succinyl-CoA
Glycolysis Catabolism of glucose into pyruvate; mostly oxygen independent, particularly when NAD+ is regenerated by
fermentation of pyruvate to lactate
Glutaminolysis Conversion of glutamine into glutamate; glutamate can be oxidatively or non-oxidatively converted to anaplerotic α-ke to
glutarate
ROS Reactive oxygen species; produced by NADPH oxidases, and of particular importance, produced by OXPHOS complex I
and complex III; low levels appear to be required for normal cell functioning, whereas levels above particular thresholds
are overtly cytotoxic
OXPHOS is also likely to be affected by de novo pyrimidine syn-
thesis. De novo pyrimidine synthesis is indispensable in rapidly
proliferating cells in order to provide the heterocyclic aromatic
precursors required for DNA, RNA, phospholipid, and glycopro-
tein formation (Evans and Guy, 2004; Hail et al., 2010b). This is
especially true in vivo given the fact that the liver keeps the circu-
lating levels of pyrimidines relatively low, thus limiting the role of
pyrimidine salvage in the biochemical processes linked with cell
proliferation (Traut, 1994).
Specifically, the oxidation of dihydroorotate via the activity
of dihydroorotate dehydrogenase (DHODH, EC 1.3.99.11, the
rate-limiting enzyme for the de novo pathway of pyrimidine syn-
thesis) provides electrons for OXPHOS in a Krebs cycle- and
glucose-independent manner thereby supporting mitochondrial
bioenergetics and the proliferative capability of various cell types
(Löffler, 1989), including hematopoietic cells (Xu et al., 1996;
Rückemann et al., 1998; Sawamukai et al., 2007; Ringshausen et al.,
2008). Coenzyme Q functions as the proximal electron acceptor
for the oxidation of dihydroorotate to orotate by DHODH, and
cytochrome c oxidase serves as the ultimate electron acceptor for
this reaction. In this scenario, dihydroorotate functions as a reduc-
ing equivalent like NADH or succinate to modulate mitochondrial
OXPHOS (Hail et al., 2010a) (Figure 2). In fact, the activity of
DHODH is believed to be a major contributor to mitochondrial
oxygen consumption in leukemia cells (Beuneu et al., 2000). Con-
sequently, if DHODH and de novo pyrimidine biosynthesis are
constitutively active in transformed hematopoietic cell this would
not only affect their rate of proliferation (Shawver et al., 1997;
Rückemann et al., 1998), but also their endogenous mitochondrial
reactive oxygen species (ROS) production (Forman and Kennedy,
1975; Lakaschus et al., 1991; Lenaz, 2001). The very nature of this
paired metabolic activity could serve as a feed-forward mechanism
for leukemogenesis since ROS play an integral role in mutagene-
sis and oncogenic signaling (Hail and Lotan, 2009). Furthermore,
DHODH activity in response to cell proliferation can function
under a seemingly wide (i.e., ≥0.13%) range of oxygen ten-
sion, suggesting that aerobic conditions bordering on moderate
hypoxia are theoretically sufficient to support OXPHOS and de
novo pyrimidine synthesis (Löffler, 1989; Amellem et al., 1994).
Third, although OXPHOS is metabolically more efficient than
glycolysis in terms of ATP generation, glycolysis occurs in the
cytosol which typically represents>70% of the cell volume (Luby-
Phelps, 2000) and thus has the potential of matching net ATP
contributions from OXPHOS which occurs in the smaller volume
of the mitochondrial matrix and inner membrane. In addition,
OXPHOS depends on adequate amounts of oxygen and may not
be sustainable under high rates of electron transport in rapidly
dividing cells. Furthermore, oxygen levels are markedly reduced
in the leukemic bone marrow niche (Benito et al., 2011). In dis-
cussing this latter point, it is important to consider that although
glycolysis depends on the availability of NAD+ for the reaction
catalyzed by glyceraldehyde-3-phosphate dehydrogenase, limiting
the availability of oxygen – the canonical final acceptor of elec-
trons from NADH – may not be critical as this oxidized cofactor
can be readily formed by the fermentation of pyruvate to lactate.
As such, depending on glycolysis instead of OXPHOS becomes a
distinct advantage for proliferating leukemia cells in the hypoxic
bone marrow niche.
Fourth, reduced dependence on OXPHOS for ATP genera-
tion favors the use of Krebs cycle intermediates for biosynthetic
reactions. For instance, citrate cataplerosis from the Krebs cycle
provides cytosolic acetyl-CoA for de novo fatty acid synthesis
(FAS), and succinyl-CoA cataplerosis from the cycle provides car-
bon skeletons for the synthesis of heme groups (Berg et al., 2002)
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FIGURE 1 | Reprogramed pathways of intermediary metabolism.
Incomplete oxidation of glucose carbon skeletons provides intermediaries for
biosynthesis, while fermentation of pyruvate to lactate regenerates NAD+ for
the glycolytic conversion of glyceraldehydes-3-phosphate (GAD-3-P) to
1,3-bisphosphoglycerate and subsequent formation of 3-phosphoglycerate
(3-PG). In order to maintain an adequate supply of biosynthetic intermediates
in the absence of pyruvate-derived oxaloacetate (OAA), Krebs cycle activity
relies on glutamine anaplerosis to regenerate alpha-ketoglutarate (α-KG; and
potentially aspartate anaplerosis). Regeneration of cataplerotic citrate also
relies on FAO-derived acetyl-CoA. Please refer to the text for additional details.
(Figure 1). These cataplerotic reactions of the Krebs cycle not
only provide intermediates for biosynthesis, but when followed by
anaplerotic reactions to regenerate oxaloacetate, also reduce the
amount of NADH generated in the cycle. One should consider that
citrate cataplerosis followed byα-ketoglutarate anaplerosis via glu-
taminolysis produces one less NADH than if citrate continued in
the cycle; similarly, succinyl-CoA cataplerosis followed by oxaloac-
etate anaplerosis via transamination of aspartate or carboxylation
of pyruvate produces one less NADH and one less FADH2 than if
succinyl-CoA continued in the cycle. Taken together, it is intrigu-
ing to postulate that a “leaky” or truncated Krebs cycle can bypass
in large part the requirement for sustained oxygen levels while
at the same time providing critical intermediates for biosynthetic
reactions.
Lastly, seminal work by Bonnet et al. (2007) demonstrated
that in solid tumor cell lines the mitochondrial oxidation of
pyruvate – induced pharmacologically by dichloroacetate (DCA) –
promotes ROS generation and cell death, suggesting that oxi-
dizing other carbon sources different from glucose may ipso
facto be favorable in terms of cell survival. While there is no
experimental evidence of a similar toxic effect of pyruvate oxi-
dation in leukemia cells, it is important to consider the possibility
that leukemia cells may also forgo pyruvate oxidation to maintain
cell viability.
REGULATORY ADAPTATIONS
Leukemia cells must have acquired mechanisms to bypass the
inhibitory effect of ATP accumulation on glycolysis, particularly
at the point of phosphofructokinase 1 (PFK-1), the canonical
regulator of glycolysis that carries out the conversion of fructose-
6-phosphate into fructose-1,6-bisphosphate. Recent evidence sug-
gests that in lymphoma (Nb2-11) and leukemia (TF-1) cell lines,
PFK-1 has been post-translationally modified via a proteinase K-
type of mechanism resulting in a shorter polypeptide which main-
tains catalytic activity, but is missing the allosteric sites required for
inhibition by citrate, ATP, and phosphoenolpyruvate (Smerc et al.,
2011). Intriguingly, the truncated enzyme is super-activated by
fructose-2,6-bisphosphate (Smerc et al., 2011). Although similar
modifications have not been reported in primary leukemia sam-
ples, it is intriguing to speculate that bypassing inhibitory effects
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FIGURE 2 | A diagrammatic depiction of DHODH in the inner
mitochondrial membrane illustrating its role in mitochondrial
bioenergetics and de novo pyrimidine synthesis. Please refer to the text
for additional details (abbreviations: I, complex I; II, complex II; III, complex
III; IV, complex IV; FMN, flavin mononucleotide).
of intracellular ATP accumulation could generate a critical growth
advantage of leukemia vs. normal progenitors.
In addition to resisting the inhibitory effects of ATP accumu-
lation on glycolysis, leukemia cells also use mitochondria-derived
ATP to accelerate the rate of glucose activation and hence gly-
colysis. Over two decades ago, Arany et al. (1988) reported that
the glycolytic enzyme hexokinase promoted oxygen consumption
in leukemia cells when it associated with the outer mitochondr-
ial membrane, suggesting perhaps a novel link between glycolysis
and electron transport. More recent evidence (reviewed in Math-
upala et al., 2010) indeed supports the notion that a particular
isoform of hexokinase (HK), HKII associates with mitochondria
to attain direct access to OXPHOS generated ATP for the phos-
phorylation of glucose. Additionally, the kinase AKT – a known
activator of glycolysis in leukemia cells – phosphorylates HKII and
is thus promoting its localization to the outer mitochondrial mem-
brane (Majewski et al., 2004a,b). Phosphorylated HKII associates
with VDAC, the outer mitochondrial membrane anion channel
that allows entry of most metabolites, but only permits egress
of pro-apoptotic proteins when the intrinsic pathway of pro-
gramed cell death is activated (reviewed in Shoshan-Barmatz et al.,
2010; Shoshan-Barmatz and Ben-Hail, 2012). Since mitochondria-
bound HKII inhibits apoptosis in leukemia and lymphoma cell
lines (Chen et al., 2009), it is intriguing to speculate that HKII pre-
vents cytochrome c release by blocking the channel space in VDAC
(Abu-Hamad et al., 2008), although conflicting reports suggest
that the antiapoptotic effect of HKII may be instead dependent on
the presence and/or activity of Cyclophilin D and ANT (Chiara
et al., 2008). Regardless of the precise mechanisms, it is clear that
HKII critically links mitochondrial metabolism, glycolysis, and
survival in leukemia cells.
MITOCHONDRIAL UNCOUPLING: LESSONS FROM THE
MICROENVIRONMENT
In 1956, Otto Warburg acknowledged an alternative hypothesis
put forth by Feodor Lynen suggesting that the increased depen-
dence of cancer cells on glycolysis stems not from their inability
to reduce oxygen, but rather from their inability to synthesize
ATP in response to the mitochondrial proton gradient [∆ΨM
(Warburg, 1956)]. Lynen’s hypothesis was based on his own obser-
vations (Lynen, 1951) and previous work by Ronzoni and Ehren-
fest (1936) using the prototypical protonophore 2,4-dinitrophenol
(2,4-DNP), which causes a “short circuit” in the electrochemi-
cal gradient that abolishes the mitochondrial synthesis of ATP,
and decreases the entry of pyruvate into the Krebs cycle. Since
Ronzoni and Ehrenfest (1936) observed that 2,4-DNP induced an
increase in oxygen consumption, and at the same time an increase
in pyruvate conversion to lactate, it must have been tempting to
hypothesize (although they did not) that electrons for the mole-
cular reduction of oxygen must be coming from carbon sources
different from glucose. Recent work has supported this hypothesis
by demonstrating that the abrogation of ATP synthesis in response
to ∆ΨM (“mitochondrial uncoupling”) results in a preferential
oxidation of non-glucose carbon sources to maintain mitochon-
drial function and an increase in lactate generation under aerobic
conditions (Samudio et al., 2008, 2010; Sheets et al., 2008).
In leukemia cells mitochondrial uncoupling has been reported
to recapitulate the Warburg effect and support a shift toward fatty
acid oxidation (FAO) (Samudio et al., 2008, 2010). On one hand,
it is important to point out that FAO induces an uncoupling
and/or thermogenic phenotype in various cell types (reviewed
in Gambert and Ricquier, 2007); on the other hand it is also evi-
dent that increased FAO during mitochondrial uncoupling may
require anaplerotic reactions – in particular pyruvate carboxyla-
tion, glutaminolysis, and aspartate transamination – to replenish
oxaloacetate for efficient Krebs cycle use of fatty acid-derived
acetyl-CoA (Goodwin and Taegtmeyer, 2000). Indeed glutaminol-
ysis has been reported in lymphoma cell lines (Le et al., 2012),
and unpublished observations from our group suggest that glu-
tamine supports oxygen consumption in leukemia cells. Taken
together, the above data support the concept – and indirectly,
Lynen’s hypothesis – that the Warburg effect could be the result of
glutaminolysis-dependent FAO.
MITOCHONDRIAL UNCOUPLING AND CELL SURVIVAL: THE
ROLE OF Bcl-2
In leukemia cells mitochondrial uncoupling promotes resistance to
intrinsic apoptosis via, in part, antagonism of Bax/Bak oligomer-
ization (Samudio et al., 2010). Uncoupling and chemoresistance
are exacerbated in leukemia cells cultured on mesenchymal stro-
mal feeder layers (Samudio et al., 2008), and previous reports
indicate that stromal coculture upregulates Bcl-2 and Bcl-xL
in leukemia cells (Konopleva et al., 2002) suggesting that the
leukemia microenvironment promotes chemoresistance via, in
part, by potentiation of the antiapoptotic function and/or expres-
sion of Bcl-2 family members. In addition, since mitochondrial
uncoupling in leukemia cells is associated with a shift toward
FAO and away from glucose oxidation (Samudio et al., 2010),
it is tempting to speculate that the leukemia microenvironment
also signals leukemia cells to spare glucose carbon skeletons for
the generation of biomass (Samudio et al., 2009). Notably, phar-
macologic inhibition of FAO was cytotoxic and chemosensitizing
to leukemia cells cultured on bone marrow stromal feeder layers,
promoting Bax/Bak oligomerization (Samudio et al., 2010). Most
Frontiers in Oncology | Molecular and Cellular Oncology April 2013 | Volume 3 | Article 67 | 4
Vélez et al. Reprograming of intermediary metabolism in leukemia
importantly, pharmacologic inhibition of FAO demonstrated a
therapeutic benefit in combination with chemotherapy in mouse
models of human leukemia (Samudio et al., 2010), suggesting that
the shift toward FAO is a bona fide target for the treatment of hema-
tological malignancies. Nevertheless, it is unclear whether FAO or
electron transport per se antagonizes apoptosis in leukemia cells. In
addition, the mechanisms by which FAO and/or electron transport
regulate Bax/Bak oligomerization remain to be elucidated.
Recent work has suggested that Bcl-2 overexpression defines a
subset of OXPHOS-dependent, ROS-low, quiescent leukemia stem
cells (LSC), in which pharmacologic or genetic inhibition of Bcl-
2 rapidly diminishes oxygen consumption capacity and increases
ROS generation prior to the onset of apoptosis (Lagadinou et al.,
2013). Although the precise mechanisms by which pharmacologic
inhibition of Bcl-2 antagonize electron transport in LSC remain
unclear, it is known that Bcl-2 displays an antioxidant function
in mitochondria by facilitating the import of reduced glutathione
into the mitochondrial matrix (Wilkins et al., 2012),and by directly
reducing ROS generation (Low et al., 2010). In addition, Bcl-2
protects leukemic cells against mitochondrial uncoupling-induced
apoptosis (Armstrong et al., 2001), and multiple other cell types
against palmitate-induced apoptosis (de Pablo et al., 1999; Kui
et al., 2009), suggesting that Bcl-2 may protect cells under meta-
bolic overload of the electron transport chain. In light of the
above, it is tempting to speculate that dependence on OXPHOS or
increased rates of electron transport – such as observed in mito-
chondrial uncoupling – necessitates the accompaniment of Bcl-2
to safeguard mitochondrial integrity. It is of utmost importance
to elucidate the precise molecular events that connect Bcl-2, apop-
tosis, and electron transport in leukemia cells in order to develop
effective therapies to eradicate the elusive LSC.
THE HYPOXIC BONE MARROW NICHE AND METABOLISM:
THE REVERSE KREBS CYCLE
It is intriguing that in the bone marrow, although it constitutes
a highly vascularized sinusoidal cavity, the oxygen concentra-
tion appears to be similar to that found in venous blood (i.e.,
6%) (Fiegl et al., 2009) or even lower in the stem cell niche
(i.e., 1%) (Benito et al., 2011), suggesting the notion that the
bone marrow is ipso facto hypoxic, at least physiologically. How-
ever, if leukemia cell mitochondria are indeed uncoupled in vivo,
the mechanism by which oxygen tension is reduced in the bone
marrow may be directly related to the increased oxygen reduc-
ing capacity of leukemia cells. Still, this presents an interesting
paradox: the reduced oxygen tension would eventually lead to an
inhibition of Krebs cycle activity – via accumulation of NADH –
and the reduced generation of ATP and biomass. Or will it?
Intriguing recent research has suggested that under hypoxic con-
ditions the Krebs cycle can actually go in reverse, starting from
glutamine-derived α-ketoglutarate to form citrate via reductive
carboxylation, to support the de novo synthesis of fatty acids
(Wise et al., 2011; Metallo et al., 2012). Although no evidence
of this effect has been reported in leukemia cells under hypoxia
(Figure 2 speculates on the possibility of this event), it is tempt-
ing to consider that reductive carboxylation of α-ketoglutarate
may rescue biomass generation from the Krebs cycle in leukemia
cells under reduced oxygen tension, whether this resulted from
cell autonomous consumption of available oxygen, or from yet
unidentified anatomical and/or microenvironmental effects. Like-
wise, it is intriguing to consider that if reductive carboxylation of
α-ketoglutarate is accompanied by increased conversion of NADH
to NADPH (via NADH kinase), it may also represent a rescue
mechanism against the inhibitory effects of NADH accumulation
on the Krebs cycle under conditions of reduced oxygen partial
pressure. Nevertheless, the reverse Krebs cycle faces some theoret-
ical hurdles that would have to be addressed. First, it is unclear
if sufficient amounts of α-ketoglutarate, HCO−3 , and NADPH
(reductive carboxylation of α-ketoglutarate requires NADPH via
mitochondrial IDH2) are available in the mitochondrial matrix
to promote the thermodynamically spontaneous formation of
isocitrate. Second, it is kinetically improbable that isocitrate dehy-
drogenase, an enzyme that does not contain biotin, can catalyze
carboxylation of α-ketoglutarate to form isocitrate. Perhaps a
human ortholog of 2-oxoglutarate carboxylase (found in a variety
of microorganisms; Reaction: ATP+ 2-oxoglutarate+HCO−3 =
ADP + phosphate + oxalosuccinate; EC 6.4.1.7) that can more
readily catalyze carboxylation of α-ketoglutarate (2-oxoglutarate)
into oxalosuccinate, which is then converted to isocitrate by
IDH2, could account for the observed reversal of the Krebs cycle.
However, whether this enzyme activity is expressed in leukemia
cells, and whether leukemia cells can in fact generate isocitrate
from – ketoglutarate, remains to be determined.
CONCLUDING REMARKS: WARBURG ANDWEINHOUSE
RECONCILE
A preponderance of evidence supports Warburg’s observation
that cancer cells rely on glycolysis to meet their energy demands,
although common, generalized defects in mitochondrial oxida-
tive capacity have yet to be identified for the vast majority of
cancers. In fact, more recent evidence has confirmed that cancer
cells maintain the ability to oxidize pyruvate, albeit under condi-
tions that were pharmacologically induced by DCA. Nevertheless,
the concomitant ROS generation caused by this process is con-
ceivably cytotoxic and, as such, could impinge on cell viability
(Bonnet et al., 2007). At first, it may seem intriguing that Warburg’s
hypothesis – that an irreparable damage to the oxygen reduction
capacity of tumor cells promotes the origin of cancer – survived for
nearly 50 years, especially as experimental evidence generated by
contemporary biochemist Sydney Weinhouse demonstrated that
tumor cells consumed oxygen at a rate similar, or higher than,
their normal counterparts (reviewed in Weinhouse, 1972). Addi-
tionally, to biochemistry students familiar with the amphibolic
importance of the Krebs cycle, and its apparent dependence on
oxygen to accept electrons from NADH for it normal “clock-
wise” functioning, it must seem like an obvious conclusion that
proliferating cells – tumor or normal – require an intact oxygen
reduction capacity to generate important metabolic intermediates
such as citrate, α-ketoglutarate, succinyl-CoA, and oxaloacetate.
However, one must remember that the Krebs cycle was unknown
to Warburg for nearly 10 years after his initial observations of res-
piratory impairment of cancer cells, when his former research
assistant, Sir Hans Adolf Krebs, published two seminal papers that
described the citric acid cycle (Krebs and Johnson, 1937; Krebs
et al., 1938). Moreover, it then took several decades beyond that to
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FIGURE 3 | Proposed paradigm for the reprograming of intermediary
metabolism in leukemia cells. (A) Leukemia cells cultured alone engage
in aerobic glycolysis, and maintain an intact Krebs cycle which is capable
of oxidizing pyruvate-derived acetyl-CoA, fatty acid-derived acetyl-CoA, and
possibly glutamine carbon skeletons. Their energy demands are met
through glycolysis and perhaps to some extent through mitochondrial
OXPHOS, although mitochondria may display a proclivity for uncoupling
electron transport from ATP synthesis. In monoculture, leukemia cells are
most sensitive to apoptosis induction. (B) Coculture of leukemia cells with
bone marrow-derived stromal cells promotes mitochondrial uncoupling.
Under coculture conditions leukemia cells augment aerobic glycolysis and
increase Krebs cycle activity in a manner dependent on anaplerotic
reactions – in particular glutaminolysis, and to a lesser extent pyruvate
carboxylation. The increased Krebs cycle activity does not oxidize
pyruvate-derived acetyl-CoA, but instead metabolizes large quantities of
fatty acid-derived acetyl-CoA to sustain increased rates of oxygen
consumption, that may contribute to the generation of local hypoxic
conditions. Mitochondrial uncoupling in leukemia cells is associated with
increased expression of UCP-2, and increased resistance to apoptotic
stimuli that induce Bax/Bak-dependent MOMP.
fully understand the amphibolic nature of the Krebs cycle. In the
end, Warburg’s imposing personality and his outstanding achieve-
ments ensured that his hypothesis survived – nearly unchallenged
if not for Weinhouse – for almost 50 years.
Can the observations of Weinhouse and Warburg be rec-
onciled? The evidence presented here suggests that, at least in
leukemia cells, they can. On one hand, our recent data sup-
port Feodor Lynen’s hypothesis that increased lactate generation
can be promoted under normal oxygen tension through mito-
chondrial uncoupling – induced by coculture with bone marrow
mesenchymal stromal cells – in the absence of permanent, trans-
missible defects in oxygen consumption capacity. On the other
hand, our observation that leukemia cells sustain molecular oxy-
gen reduction rates utilizing electrons derived from FAO is in
agreement with the work of Weinhouse utilizing transplantable
hepatomas (Bloch-Frankenthal et al., 1965). Indeed, it would
appear that Warburg and Weinhouse were looking at two sides
of the same coin: aerobic glycolysis and FAO, which are ele-
gantly connected by Feodor Lynen’s mitochondrial uncoupling
theory.
While is important to point out that this review has focused
predominantly in hematological malignancies, our data parallels
recent observations in solid tumors where glutamine-dependent,
glucose-independent Krebs cycle activity has been reported in
glioblastoma and melanoma cells (Scott et al., 2011). In addition,
our observation that mitochondrial uncoupling in leukemia cells
is associated with increased resistance to apoptosis is consis-
tent with the work of Derdak et al. (2008) who demonstrated
a similar paradigm in colon cancer cells. As such, we hypothe-
size that our model may indeed be broadly applicable to other
tumor types since there is presently insufficient evidence to suggest
otherwise.
Based on analysis of the literature and our own data, we pro-
pose a paradigm (Figure 3) for mitochondrial uncoupling in
hematological malignancies built on four salient foundations:
(1) mitochondrial uncoupling promotes an adequate energy bal-
ance through aerobic glycolysis, and sustains biomass generation
through cataplerotic reactions from the Krebs cycle; (2) mito-
chondrial uncoupling can orchestrate functional changes in mito-
chondria that accompany resistance to intrinsic apoptotic stimuli,
mediated, in part, by modulation of the Bcl-2 rheostat; (3) mito-
chondrial uncoupling is regulated by, and regulates the bone mar-
row microenvironment, perhaps contributing to cellular hypoxia;
and (4) mitochondrial uncoupling depends on anaplerotic reac-
tions to regenerate oxaloacetate in the Krebs cycle to support fatty
acid-dependent oxygen consumption. Whether or not this par-
adigm can be targeted for therapeutic benefit in patients with
leukemia will largely depend on a thorough understanding of the
limiting reactions that support the altered metabolic behavior of
leukemia cells.
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